Naito K, Hisazumi H, Saka A, Nakamura T, Kanda S, Mikawa I, Ejiri S, Miyagi T, Katsumi T, Kitagawa K
Department of Urology, School of Medicine, Kanazawa University.
Hinyokika Kiyo. 1990 Apr;36(4):487-94.
To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control. UFT was given orally 400 mg a day for 6 months. Of 111 patients, 56 were given UFT and 55 were followed up without any medication. The non-recurrence rate in the group treated with UFT was 62.8% after 1 year and 36.3% after 2 years of follow up, and that of the control group was 45.7% and 39.5%, respectively. The rate of non-recurrence in the UFT group was significantly higher (p less than 0.05) than that of the control group during the period of follow up for 2 years. The incidence of side effects was 6.8% in UFT patients. These results indicate the clinical usefulness of prophylactic administration of UFT for bladder cancer patients.
为评估优福定（一种氟尿嘧啶和尿嘧啶按1:4比例混合的药物）预防膀胱癌术后复发的效果，我们进行了一项以非用药组为对照的随机对照研究。优福定口服给药，每日400毫克，持续6个月。111例患者中，56例给予优福定，55例未用药进行随访。随访1年后，优福定治疗组的无复发率为62.8%，随访2年后为36.3%，而对照组分别为45.7%和39.5%。在2年的随访期内，优福定组的无复发率显著高于对照组（p小于0.05）。优福定治疗患者的副作用发生率为6.8%。这些结果表明优福定预防性给药对膀胱癌患者具有临床实用性。
